- (Stribild)) Emtricitabine/rilpivirine/tenofovir
alafenamide (
Odefsey) —
approved in the
United States in
March 2016, and in the
European Union...
-
Descovy Emtriva Epclusa Genvoya Harvoni Hepsera Letairis Lexiscan Macugen Odefsey Ranexa Sovaldi Stribild Tamiflu Truvada Tybost Veklury Vemlidy Viread Vosevi...
- (TAF) was
approved for use in the US in
March 2016 with the
brand name
Odefsey. Dolutegravir/rilpivirine, sold
under the
brand name Juluca, is a fixed-dose...
- tenofovir alafenamide
elvitegravir cobicistat November 5, 2015
Gilead Sciences Yes
Odefsey emtricitabine tenofovir alafenamide rilpivirine March 1, 2016
Gilead Sciences...
- regimens,
including Truvada, Atripla, Complera, Stribild, Descovy, Genvoya,
Odefsey, Descovy, Biktarvy, and Symtuza. Like 3TC, FTC was
found to be
active against...
-
Atripla (2006), Complera/Eviplera (2011),
Stribild (2012),
Genvoya (2015),
Odefsey (2016),
Descovy (2016),
Vemlidy (2016),
Biktarvy (2018),
Symtuza (2018)...
-
Gilead Sciences' Stribild, Complera, TAF (Tenofovir Alfonamide), Genvoya,
Odefsey and GS 9883, as well as Merck's non-nucleoside
reverse transcriptase inhibitor...
-
tenofovir alafenamide (TAF) was
approved in
March 2016
under the
brand name
Odefsey.[citation needed] In 2007 a new
family of
triazole NNRTIs was presented...
